-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21

Benzinga·09/14/2026 17:24:37
语音播报
B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Buy and raises the price target from $5 to $21.